Research Article
Critical Success Factors for Competitive Advantage in Iranian Pharmaceutical Companies: A Comprehensive MCDM Approach
Table 4
Computation of the Delphi method.
| | | DM1 | DM2 | DM3 | DM4 | DM5 | DM6 | DM7 | DM8 | DM9 | Average |
| | Formal strategy planning | 5 | 4 | 5 | 4 | 3 | 5 | 2 | 5 | 4 | 4.11 | | New technology | 3 | 2 | 4 | 5 | 2 | 3 | 5 | 2 | 4 | 3.33 | | Manufacturing strategy | 5 | 5 | 4 | 5 | 4 | 3 | 2 | 5 | 4 | 4.11 | | Modularization of production | 3 | 4 | 2 | 3 | 5 | 4 | 2 | 3 | 5 | 3.44 | | Manufacturing involvement | 5 | 4 | 5 | 5 | 3 | 2 | 5 | 4 | 4 | 4.11 | | Supplier involvement | 5 | 4 | 5 | 4 | 3 | 5 | 5 | 4 | 3 | 4.22 | | Product specification | 5 | 5 | 5 | 4 | 3 | 2 | 5 | 4 | 2 | 3.89 | | Product capability | 3 | 2 | 3 | 2 | 4 | 2 | 3 | 2 | 5 | 2.89 | | On-time new product launch | 3 | 2 | 3 | 4 | 3 | 5 | 3 | 2 | 4 | 3.22 | | Product innovation | 5 | 4 | 5 | 4 | 2 | 3 | 5 | 4 | 5 | 4.11 | | Customer support | 5 | 5 | 4 | 4 | 5 | 2 | 3 | 5 | 4 | 4.11 | | Infrastructural organization | 5 | 5 | 4 | 5 | 5 | 4 | 2 | 3 | 5 | 4.22 | | Cost | 4 | 4 | 5 | 5 | 4 | 2 | 3 | 5 | 4 | 4.00 | | Quality | 5 | 5 | 5 | 4 | 5 | 4 | 3 | 2 | 5 | 4.22 | | Delivery | 5 | 4 | 2 | 3 | 5 | 4 | 5 | 4 | 5 | 4.11 | | Flexibility | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 2 | 3 | 4.00 | | Customer satisfaction | 5 | 4 | 5 | 5 | 5 | 4 | 2 | 3 | 5 | 4.22 |
|
|
